All News

Expert oncologists review the clinical data supporting the use of sacituzumab govitecan in metastatic triple-negative breast cancer.

Patients with tenosynovial giant cell tumors, a rare locally aggressive neoplasm, who are unable to undergo surgery may benefit from treatment with pimicotinib.

Investigators will evaluate DK210 in a first-in-human phase 1 clinical trial following the FDA’s review of an investigational new drug application for the compound for locally advanced or metastatic EGFR-positive solid tumors.

The FDA has approved Guardant 360 CDx as a companion diagnostic for elacestrant in patients with ESR1-mutant, estrogen receptor–positive, HER2-negative advanced or metastatic breast cancer.

Experts review key clinical data and current treatment strategies for renal cell carcinoma following updates from the 2022 IKCS meeting.

Maintenance olaparib plus bevacizumab may improve survival in patients with high-grade ovarian cancer regardless of BRCA mutation location, according to a subgroup analysis of the PAOLA-1/ENGOT-ov25 trial.

The emergence of using hypofractionated radiation treatments—fewer radiation treatments at larger doses—across cancer types may place financial strain on radiation oncologists, but one expert notes there’s still continued success.

Results from the phase 1/2 CodeBreaK 100 trial indicate that sotorasib yields positive anticancer activity and safety in patients with pancreatic cancer harboring KRAS p.G12C mutations.

Investigators say that a phase 1/2 trial evaluating MGTA-117 in 2 hematologic malignancies has been paused following a serious adverse effect that may be related to the agent.

“Nonetheless, we saw tremendous benefits for these patients, patients who didn’t benefit from other treatments, and it was exciting to be involved with this early research.”

Combining bispecific antibodies with other agents such as R-CHOP and R-CHP for various subtypes of lymphoma has the potential to produce exciting results, according to an expert from Dana-Farber Cancer Institute.

Richard L. Martin III, MD, MPH, and Stephen Schleicher, MD, MBA, share a perspective on rural cancer care.

Early study results show that an artificial intelligence model may help oncologists better stratify patients with prostate cancer into risk groups than existing methods, according to an expert.

Adding radiation to sorafenib elicited a survival improvement in a group of patients with hepatocellular carcinoma, a type of liver cancer.

Minh-Tri Nguyen, MD, and colleagues investigate the association between time to treatment, socioeconomic status, and clinical outcomes among rural and urban patients with breast cancer.

Patients with estrogen receptor–positive, HER2-negative metastatic breast cancer can now receive elacestrant as treatment following the FDA’s approval of the agent.

The approval for pirtobrutinib in the treatment of patients with relapsed or refractory mantle cell lymphoma was based on data from the phase 1/2 BRUIN trial.

The use of circulating tumor DNA in patients with advanced colorectal cancer may provide early insight into who is and is not responding to treatment, according to an expert from Weill Cornell Medicine.

Qianyue Deng, MD, and colleagues examine the efficacy of thoracic radiotherapy for the treatment of unresectable non-small cell lung cancer.

The European Commission approval for trastuzumab deruxtecan in HER2-low metastatic breast cancer is based on data from the phase 3 DESTINY-Breast04 trial.

Adjuvant chemotherapy following multiagent neoadjuvant chemotherapy and surgical resection produced better overall survival among patients with pancreatic ductal adenocarcinoma vs those who did not receive adjuvant treatment.

The FDA approved adjuvant pembrolizumab for the treatment of patients with resected non–small cell lung cancer, based on data from the phase 3 KEYNOTE-091/EORTC-1416-LCG/ETOP-8-15-PEARLS trial.

Tamibarotene is a first-in-class oral first-in-class selective retinoic acid receptor α agonist that is being evaluated in combination with azacitidine for newly diagnosed higher-risk myelodysplastic syndrome.

Black and Hispanic patients are less likely to receive opioids than their White counterparts; bias training and logistical support may act as potential strategies to mitigate these disparities, according to an expert from Dana-Farber Cancer Institute.

Treatment with avutometinib and defactinib in patients with low-grade serous ovarian cancer resulted in a positive objective response rate.

Co-editor-in-Chief Howard S. Hochster, MD, discusses disparities in access to health care between urban and rural patients with breast cancer, and how they might be addressed.

Data from a ctDNA analysis of the phase 3 INTRIGUE study indicate that KIT mutational status may be associated with response to certain Tyrosine kinase inhibitors in GIST, according to an expert from the Yale Cancer Center in New Haven, Massachusetts.

An expert from the Smilow Cancer Hospital and Yale Cancer Center indicates that findings from the ctDNA analysis of the phase 3 INTRIGUE study were “provocative” and that the subsequent phase 3 INSIGHT study has the potential to be practice changing should data be positive.

Findings from a phase 2 trial indicate that CTX-009 plus paclitaxel may produce an encouraging responses in patients with advanced biliary tract cancer, according to investigators.

Neoadjuvant pembrolizumab appears to improve outcomes in a cohort of patients with metastatic microsatellite instability–high, mismatch repair deficient solid tumors.